Revolutionary Metabolic Research Compounds
GLP-1 receptor agonists represent a breakthrough in metabolic research, offering unprecedented insights into glucose regulation, appetite control, and weight management. These sophisticated compounds work through the incretin system to provide researchers with powerful tools for studying metabolic pathways and their therapeutic potential.
Tirzepatide Dual Agonist
The world's first dual GLP-1/GIP receptor agonist, setting new standards in metabolic research with its innovative dual-pathway approach.
- Dual GLP-1/GIP receptor agonist for enhanced glycemic control
- Significant, durable weight-loss effects in clinical studies
- Improves insulin sensitivity and beta-cell function
- Reduces cardiovascular risk markers
- Superior efficacy compared to single agonists
Research Protocol
Starting Dose: 2.5 mg once weekly for 4 weeks
Titration: Increase in 2.5 mg steps every 4 weeks
Maximum: 15 mg weekly
Half-Life: ~5 days
Onset: Appetite suppression within 1-2 weeks; measurable weight-loss by 4-6 weeks
Note: Some researches may begin even lower (e.g., 0.5–1 mg/week) in very sensitive patients and titrate more slowly; always tailor to specific research plan and the subject's individual responses
Semaglutide GLP-1 Agonist
The gold standard GLP-1 receptor agonist with proven cardiovascular benefits and substantial weight-loss capabilities.
- GLP-1 receptor agonist for superior glucose control
- Substantial weight-loss and appetite control
- Cardiovascular outcome benefit in high-risk patients
- Once-weekly dosing convenience
- Extensively studied safety profile
Research Protocol
Starting Dose: 0.25 mg once weekly for 4 weeks
Escalation: 0.5 mg weekly for 4 weeks, then optionally to 1-2.4 mg
Half-Life: ~7 days
Onset: Reduced appetite in first week; weight-loss detectable in 4-5 weeks
Note: Some researches may begin even lower (e.g., 0.5–0.2 mg/week) in very sensitive patients and titrate more slowly; always tailor to specific research plan and the subject's individual responses
Retatrutide Triple Agonist
Next-generation triple agonist targeting GLP-1, GIP, and Glucagon receptors for unprecedented metabolic effects.
- Triple GLP-1/GIP/Glucagon agonist driving robust weight-loss
- Enhances energy expenditure and glucose control
- Early data show ~24% body-weight reduction at 48 weeks
- Revolutionary mechanism of action
- Phase-3 trials ongoing
Research Protocol
Starting Dose: 1.5 mg weekly
Titration: Increase to 8-12 mg per protocol
Duration: Over 48 weeks in trials
Half-Life: ~6 days (estimated)
Onset: Early satiety within 7-10 days; significant weight-loss from week 4
Note: Some researches may begin even lower (e.g., 0.5–1 mg/week) in very sensitive patients and titrate more slowly; always tailor to specific research plan and the subject's individual responses
Cagrilintide Amylin Analogue
Long-acting amylin analogue that works synergistically with GLP-1 agonists for enhanced metabolic effects.
- Long-acting amylin analogue promoting satiety
- Synergistic with semaglutide (CagriSema) for weight-loss
- Improves post-prandial glucose excursions
- Complementary mechanism to GLP-1
- Part of combination therapy research
Research Protocols
Weeks 1–4: 0.25 mg subcutaneously once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly — maintenance dose
Combination: Used in CagriSema trials
Half-Life: ~8 days
Onset: Reduced hunger within first 2 weeks
CagriSema Combination
Groundbreaking combination of Semaglutide and Cagrilintide showing superior weight-loss compared to either component alone.
- Combines Semaglutide and Cagrilintide for enhanced appetite suppression
- Synergistic effect on metabolic markers and weight reduction
- Superior weight loss compared to either component alone
- Dual pathway approach to satiety
- Investigational combo with significant potential
Research Protocols
Standard Semaglutide Dosing:
Starting Dose: 0.25 mg once weekly for 4 weeks
Escalation: 0.5 mg weekly for 4 weeks, then optionally to 1-2.4 mg
Combination Dose: 2.4 mg Semaglutide + 2.4 mg Cagrilintide weekly
Add Cagrilintide Standard Dosing At Same Time / Day of the Week:
Weeks 1–4: 0.25 mg subcutaneously once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly — maintenance dose
Half-Life: ~7-8 days combined
Onset: Appetite control within 1-2 weeks; weight loss from week 4
Understanding GLP-1 Mechanisms
These compounds work through sophisticated receptor systems to regulate metabolism, appetite, and glucose homeostasis at the cellular level.
GLP-1 Pathway
Activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and slow gastric emptying for optimal glucose control.
GIP Pathway
Glucose-dependent insulinotropic polypeptide pathway enhances insulin sensitivity and promotes healthy fat metabolism.
Glucagon Pathway
Selective glucagon receptor activation increases energy expenditure and promotes fat oxidation without adverse effects.
Amylin System
Complements incretin action by enhancing satiety signals and regulating post-meal glucose responses.
Clinical Research Highlights
Research Applications & Considerations
Metabolic Research
These compounds provide invaluable insights into incretin biology, glucose homeostasis, and the complex interplay between appetite regulation and metabolic health.
Quality & Purity
All peptides undergo rigorous testing for purity, potency, and stability. Each batch includes comprehensive certificates of analysis and proper storage guidelines.
Storage & Handling
Proper refrigeration (36-46°F) is essential after first use. Lyophilized peptides remain stable for extended periods when stored correctly. Always use sterile reconstitution techniques.
Advance Your Metabolic Research
Discover the full potential of incretin-based research with our premium GLP-1 peptide collection.
Discover Some of Our Products